Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Relay Therapeutics (Nasdaq: RLAY) plans to report its fourth quarter and full year 2022 financial results and corporate highlights after market close on February 23, 2023. The company focuses on precision medicine by integrating computational and experimental technologies. Relay's Dynamo™ platform is designed to enhance drug discovery for challenging protein targets, particularly in oncology and genetic diseases. Relay aims to revolutionize small molecule therapeutic discovery in these areas, bringing transformative therapies to patients.
- The Dynamo™ platform enhances drug discovery by targeting previously intractable proteins.
- Focus on small molecule therapeutic discovery in oncology and genetic diseases may lead to significant breakthroughs.
- No teleconference will accompany the financial results announcement, potentially limiting investor engagement.
CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report fourth quarter and full year 2022 financial results and corporate highlights after the close of market on Thursday, February 23, 2023. The company will not be conducting a teleconference in conjunction with its financial results press release.
About Relay Therapeutics
Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Caroline Glen
617-370-8837
cglen@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Relay Therapeutics report its financial results?
What is the focus of Relay Therapeutics?
What is the Dynamo™ platform used for?
Will Relay Therapeutics conduct a conference call with its financial results?
